Our top pick for
ARCA biopharma Inc is a biotechnology business based in the US. ARCA biopharma shares (ABIO) are listed on the NASDAQ and all prices are listed in US Dollars. ARCA biopharma employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$2.67|
|52-week range||$2.65 - $5.50|
|50-day moving average||$2.90|
|200-day moving average||$3.21|
|Wall St. target price||$7.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.52|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-6.97%|
|1 month (2021-09-20)||N/A|
|3 months (2021-07-23)||-10.10%|
|6 months (2021-04-23)||-24.58%|
|1 year (2020-10-23)||-33.75%|
|2 years (2019-10-24)||-49.62%|
|3 years (2018-10-24)||378.41%|
|5 years (2016-10-24)||6.80%|
|Gross profit TTM||$0|
|Return on assets TTM||-26.07%|
|Return on equity TTM||-44.89%|
|Market capitalisation||$38.5 million|
TTM: trailing 12 months
There are currently 317,621 ARCA biopharma shares held short by investors – that's known as ARCA biopharma's "short interest". This figure is 18.3% down from 388,882 last month.
There are a few different ways that this level of interest in shorting ARCA biopharma shares can be evaluated.
ARCA biopharma's "short interest ratio" (SIR) is the quantity of ARCA biopharma shares currently shorted divided by the average quantity of ARCA biopharma shares traded daily (recently around 100195.89905363). ARCA biopharma's SIR currently stands at 3.17. In other words for every 100,000 ARCA biopharma shares traded daily on the market, roughly 3170 shares are currently held short.
However ARCA biopharma's short interest can also be evaluated against the total number of ARCA biopharma shares, or, against the total number of tradable ARCA biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ARCA biopharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ARCA biopharma shares in existence, roughly 20 shares are currently held short) or 0.0221% of the tradable shares (for every 100,000 tradable ARCA biopharma shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ARCA biopharma.
Find out more about how you can short ARCA biopharma stock.
We're not expecting ARCA biopharma to pay a dividend over the next 12 months.
ARCA biopharma's shares were split on a 1:18 basis on 3 April 2019. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ARCA biopharma shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for ARCA biopharma shares which in turn could have impacted ARCA biopharma's share price.
Over the last 12 months, ARCA biopharma's shares have ranged in value from as little as $2.65 up to $5.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ARCA biopharma's is 2.6397. This would suggest that ARCA biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ARCA biopharma, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.